We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals

31 hedge funds and large institutions have $17.3M invested in Eledon Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $15.9M → $17.3M (+$1.35M)

0% more funds holding

Funds holding: 3131 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

1.94% less ownership

Funds ownership: 47.49%45.55% (-1.9%)

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

Holders
31
Holders Change
Holders Change %
0%
% of All Funds
0.53%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
6
Reduced
12
Closed
2
Calls
$48K
Puts
Net Calls
+$48K
Net Calls Change
-$9K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$6.42M
CAM
2
Cormorant Asset Management
Massachusetts
$3.38M -$260K -81,595 -6%
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.88M
WP
4
Woodline Partners
California
$1.43M
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$1.03M -$170K -53,360 -12%
CM
6
CM Management
Florida
$676K +$63.7K +20,000 +9%
IC
7
Ikarian Capital
Texas
$612K -$448K -140,707 -39%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$357K +$2.16K +679 +0.5%
Ensign Peak Advisors
9
Ensign Peak Advisors
Utah
$241K +$32.4K +10,186 +13%
EP
10
Eversept Partners
New York
$187K +$27.6K +8,678 +15%
JE
11
JMAC Enterprises
Pennsylvania
$151K
ISL
12
Ingalls & Snyder LLC
New York
$141K
BlackRock
13
BlackRock
New York
$136K +$3.42K +1,074 +2%
State Street
14
State Street
Massachusetts
$123K
Two Sigma Advisers
15
Two Sigma Advisers
New York
$116K -$8.92K -2,800 -6%
Renaissance Technologies
16
Renaissance Technologies
New York
$88K -$955 -300 -0.9%
Northern Trust
17
Northern Trust
Illinois
$83K
Two Sigma Investments
18
Two Sigma Investments
New York
$82K -$4.46K -1,400 -4%
BFM
19
Boothbay Fund Management
New York
$61K -$40.1K -12,580 -36%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$50K +$57.2K +17,950 New
Mercer Global Advisors
21
Mercer Global Advisors
Colorado
$46K
Rockefeller Capital Management
22
Rockefeller Capital Management
New York
$4K
UBS Group
23
UBS Group
Switzerland
$3K -$11.5K -3,624 -78%
Morgan Stanley
24
Morgan Stanley
New York
$3K -$2.86K -899 -44%
TRCT
25
Tower Research Capital (TRC)
New York
$1K -$1.26K -395 -38%

ELDN Hedge Fund Activity: Q3 2022 in Review

31 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2022, worth a combined $17.3M — up 8.5% from $15.9M a quarter earlier.

Fund positioning in ELDN was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 12 trimmed.

The largest buyer was CM Management, adding an estimated $63.7K. The largest seller was Ikarian Capital, cutting an estimated $448K.

  • 31 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $17.3M of Eledon Pharmaceuticals stock for Q3 2022, up 8.5% quarter-over-quarter.
  • 2 funds opened new Eledon Pharmaceuticals positions in Q3 2022 and 2 closed out, a net change of 0 holders.
  • The largest Eledon Pharmaceuticals buyer in Q3 2022 was CM Management, an estimated $63.7K added.
  • The largest Eledon Pharmaceuticals seller in Q3 2022 was Ikarian Capital, an estimated $448K sold.

Based on aggregated 13F filings for Q3 2022.